Education
About Us
Working with TipRanks
Follow Us
SynAct Pharma AB (SE:SYNACT)
:SYNACT
SYNACT Stock Chart & Stats
kr20.65
-kr0.24(-1.33%)
At close: 4:00 PM EST
kr20.65
-kr0.24(-1.33%)
Day’s Range― - ―
52-Week Rangekr8.90 - kr25.30
Previous CloseN/A
Volume43.49K
Average Volume (3M)214.83K
Market Cap
€1.22B
Enterprise Valuekr871.84M
Total Cash (Recent Filing)€68.89M
Total Debt (Recent Filing)€1.54M
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Feb 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.66
Price to Sales (P/S)0.00
P/FCF Ratio-3.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr8.90 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €1.22B.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Feb 18, 2026 which is in 64 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Oct 30, 2025. The company reported -kr0.675 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.675.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.675 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.216%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB (SYNACT) is a biotechnology company focused on the development of pharmaceuticals for the treatment of inflammatory diseases. The company's primary aim is to advance therapies that can modulate the body's immune response to inflammation, targeting unmet medical needs across various conditions. SynAct Pharma's lead product candidate is designed to leverage its platform technology to achieve these therapeutic goals.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---